Adefovir, a nucleotide analogue, has been pivotal in the therapeutic landscape, initially explored for HIV and later finding significant utility in the management of chronic hepatitis B virus (HBV) infection. Adefovir inhibits viral replication by interfering with the reverse transcriptase enzyme essential for HBV replication, demonstrating its efficacy in suppressing viral activity. The prodrug, adefovir dipivoxil, is administered orally and undergoes conversion to the active form, adefovir, in the body. It is indicated for the treatment of chronic HBV infection in adults, particularly in cases with active viral replication and evidence of liver disease. Adefovir dipivoxil has been part of the armamentarium for managing hepatitis B, demonstrating antiviral efficacy and contributing to improved clinical outcomes. Renal toxicity is a notable consideration with adefovir, requiring ongoing monitoring of renal function during treatment. The risk of resistance development underscores the importance of careful management, considering alternative antiviral agents or combination therapies when necessary. As research continues to advance antiviral therapies, adefovir remains a valuable option in the treatment of chronic hepatitis B, contributing to the broader goal of controlling viral replication, preventing disease progression, and improving the overall prognosis for individuals affected by HBV infection.